|
1
|
D'Andrea AD: Susceptibility pathways in
Fanconi's anemia and breast cancer. N Engl J Med. 362:1909–1919.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howlader N, Noone AM, Krapcho M, Neyman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2009 (Vintage 2009
Populations), National Cancer Institute. (Bethesda, MD). http://seer.cancer.gov/csr/1975_2009_pops09/based
on November 2011 SEER data submission, posted to the SEER web site.
April;2012.
|
|
3
|
Gurney JG, Ross JA, Wall DA, Bleyer WA,
Severson RK and Robison LL: Infant cancer in the U.S.:
Histology-specific incidence and trends, 1973 to 1992. J Pediatr
Hematol Oncol. 19:428–432. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
London WB, Castleberry RP, Matthay KK,
Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM,
Reynolds CP and Cohn SL: Evidence for an age cutoff greater than
365 days for neuroblastoma risk group stratification in the
Children's Oncology Group. J Clin Oncol. 23:6459–6465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Castleberry RP, Pritchard J, Ambros P,
Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B,
Dicks-Mireaux C, Frappaz D, et al: The International Neuroblastoma
Risk Groups (INRG): A preliminary report. Eur J Cancer.
33:2113–2116. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kitao H and Takata M: Fanconi anemia: A
disorder defective in the DNA damage response. Int J Hematol.
93:417–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mirchandani KD and D'Andrea AD: The
Fanconi anemia/BRCA pathway: A coordinator of cross-link repair.
Exp Cell Res. 312:2647–2653. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Venkitaraman AR: Tracing the network
connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer.
4:266–276. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Howlett NG, Taniguchi T, Olson S, Cox B,
Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals
G, et al: Biallelic inactivation of BRCA2 in Fanconi anemia.
Science. 297:606–609. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alter BP, Rosenberg PS and Brody LC:
Clinical and molecular features associated with biallelic mutations
in FANCD1/BRCA2. J Med Genet. 44:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Myers K, Davies SM, Harris RE, Spunt SL,
Smolarek T, Zimmerman S, McMasters R, Wagner L, Mueller R, Auerbach
AD and Mehta PA: The clinical phenotype of children with Fanconi
anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr Blood
Cancer. 58:462–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hadjisavvas A, Charalambous E, Adamou A,
Neuhausen SL, Christodoulou CG and Kyriacou K: Hereditary breast
and ovarian cancer in Cyprus: Identification of a founder BRCA2
mutation. Cancer Genet Cytogenet. 151:152–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Offit K, Levran O, Mullaney B, Mah K, Nafa
K, Batish SD, Diotti R, Schneider H, Deffenbaugh A, Scholl T, et
al: Shared genetic susceptibility to breast cancer, brain tumors,
and Fanconi anemia. J Natl Cancer Inst. 95:1548–1551. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirsch B, Shimamura A, Moreau L, Baldinger
S, Hag-alshiekh M, Bostrom B, Sencer S and D'Andrea AD: Association
of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal
instability and solid tumors of childhood. Blood. 103:2554–2559.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wagner JE, Tolar J, Levran O, Scholl T,
Deffenbaugh A, Satagopan J, Ben-Porat L, Mah K, Batish SD, Kutler
DI, et al: Germline mutations in BRCA2: Shared genetic
susceptibility to breast cancer, early onset leukemia, and Fanconi
anemia. Blood. 103:3226–3229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedenson B: The BRCA1/2 pathway prevents
hematologic cancers in addition to breast and ovarian cancers. BMC
Cancer. 7:1522007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frappart PO, Lee Y, Lamont J and McKinnon
PJ: BRCA2 is required for neurogenesis and suppression of
medulloblastoma. EMBO J. 26:2732–2742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang W: Emergence of a DNA-damage response
network consisting of Fanconi anaemia and BRCA proteins. Nat Rev
Genet. 8:735–748. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faivre L, Portnoi MF, Pals G,
Stoppa-Lyonnet D, Le Merrer M, Thauvin-Robinet C, Huet F, Mathew
CG, Joenje H, Verloes A and Baumann C: Should chromosome breakage
studies be performed in patients with VACTERL association? Am J Med
Genet A. 137:55–58. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ludwig T, Chapman DL, Papaioannou VE and
Efstratiadis A: Targeted mutations of breast cancer susceptibility
gene homologs in mice: Lethal phenotypes of Brca1, Brca2,
Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes
Dev. 11:1226–1241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hakem R, de la Pompa JL and Mak TW:
Developmental studies of Brca1 and Brca2 knock-out mice. J Mammary
Gland Biol Neoplasia. 3:431–445. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ameziane N, Errami A, Léveillé F, Fontaine
C, de Vries Y, van Spaendonk RM, de Winter JP, Pals G and Joenje H:
Genetic subtyping of Fanconi anemia by comprehensive mutation
screening. Hum Mutat. 29:159–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roa BB, Boyd AA, Volcik K and Richards CS:
Ashkenazi Jewish population frequencies for common mutations in
BRCA1 and BRCA2. Nat Genet. 14:185–187. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johannesdottir G, Gudmundsson J,
Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson
OT, Borg A, Ingvarsson S, Easton DF, et al: High prevalence of the
999del5 mutation in icelandic breast and ovarian cancer patients.
Cancer Res. 56:3663–3665. 1996.PubMed/NCBI
|
